Purpose:

Purpose : The Hydrus Microstent (Ivantis, Inc, Irvine, CA) is an innovative device designed to reduce intraocular pressure (IOP) by providing trabecular bypass and Schlemm’s canal scaffolding. In our retrospective interventional case series we assessed the efficacy and safety of the Hydrus stent implantation combined with clear lensectomy.

Results:

Results : Of 186 operated eyes that meet the criteria of better than than 20/40 pre-operative vision, 105 eyes have 6 months follow up data at the time of the abstract submission. The baseline average IOP of the 186 eyes was 14.67 ± 4.57 mmHg, mean number of medications was 2.53 ± 1.47, and average baseline visual field mean deviation was -8.36 dB. For cases with 6 months follow up, mean IOP decreased to 13.36 ± 2.92 mmHg and the mean medication count reduced to 0.45 ±1.07 (p<0.001). the="" proportion="" of="" patients="" with="" no="" medication="" has="" increased="" from="" 0%="" to="" 81%="" following="" hydrus="" and="" clear="" lensectomy.="" the="" visual="" field="" improved="" from="" a="" mean="" of="" -8.37="" db="" to="" a="" mean="" of="" -8.17db.="" the="" proportion="" of="" patients="" with="" no="" medication="" has="" increased="" from="" 0%="" to="" 81%="" following="" hydrus="" and="" clear="" lensectomy.="" the="" visual="" field="" improved="" from="" a="" mean="" of="" -8.37="" db="" to="" a="" mean="" of="">

Conclusions:

Conclusions : The Hydrus Microstent combined with clear lensectomy proves to be a safe procedure to preserve and restore aqueous outflow and achieve significant reduction in both intraocular pressure and medication burden.